Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2011-002464-24-DE
EUCTR2011-002464-24-DE
Active, not recruiting
Not Applicable

Clinical study to investigate the efficacy and safety of an estradiol containing cream (0.01 % estradiol) in patients with dermatoporosis - Efficacy of estradiol on dermatoporosis

Dr. August Wolff GmbH & Co. KG Arzneimittel0 sitesJune 17, 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsdermatoporosis stage I and IITherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
DrugsLinoladiol N

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
dermatoporosis stage I and II
Sponsor
Dr. August Wolff GmbH & Co. KG Arzneimittel
Status
Active, not recruiting
Last Updated
12 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 17, 2011
End Date
TBD
Last Updated
12 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • •dermatoporosis stage I or II, i.e at least the presence of the following symptoms: skin atrophy and senile purpura or pseudo scar, otherwise healthy skin
  • •Skin thickness \< 1mm as measured by ultrasound
  • •Clinical assessment of skin atrophy of \= 2
  • •Postmenopausal women with last menstruation \> 24 months prior study start
  • •Serum estradiol \< 30 pg/ml l
  • •skin type II to IV (Fitzpatrick) , I may be also included
  • •\= 60 years old
  • •Willingness to actively participate in the study and to come to the scheduled visits
  • •Signed written informed consent
  • •Willingness to discontinue the use of own cleansing and cosmetic products in the treatment areas throughout the course of the study

Exclusion Criteria

  • •\-Systemic treatment with drugs interfering with the immune system (in brackets: months prior to study day 1 and during conduct of study) : corticosteroids (3\), estrogen or gestagen containing drugs or exogenous steroid hormones (1\), use of estragen of gestagen injections (6\), nonsteroidal anti\-inflammatory drugs (0\.5; The intake acetylisalicylic acid is permitted if low\-dose prophylaxis or occasional intake for minor pain relief), anticoagulant intake (3\)
  • •\-Topical treatment of test areas: corticosteroids (3\), anti\-inflammatory substances (0\.5\), any of the test preparations tested in this study (1\)
  • •\-Diseases: atopic dermatitis, eczema, rosacea, allergic asthma bronchiale, hyper\- or hypotension, bradycardia or bradyarrhytmia, tachycardia or tachyarrhythmia, chronic liver disease, estrogen dependent neoplasia, class III, IV or V Papanicolaou smear or evidence of cervical dysplasia, lyomyoma or endometriosis, sickle cell anaemia, osteosclerosis, idiopathic icterus, acute infection, active skin disease, e.g. skin tumors, keloids formation, hypertrophic scarring, moderate or severe illness within the last 2 weeks before first exposure, known infectious diseases, thromboemboembolic disorders or coagulation disorders
  • •\-Known hypersensitivity against: one of the ingredients of the product, latex, local anesthetics or plasters

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Clinical study to investigate the efficacy and safety of iliac stenting in patients with peripheral arterial diseasePeripheral arterial disease(PAD), Arteriosclerosis obliterans(ASO)
JPRN-UMIN000016264Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan100
Recruiting
Phase 3
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib.
JPRN-jRCT2031220420Hibi Kazushige324
Not yet recruiting
Not Applicable
Clinical trial to investigate the efficacy and safety of fish skin-derived collagen on wall thickness in the carotid artery and clinical symptom, etc. in healthy adults and subjects with mild carotid artery hypertrophy by a double-blind parallel group comparison desigHealthy adults and subjects with mild carotid artery hypertrophy
JPRN-UMIN000026277Kojinkai Medical Corporation Shin-Nihonbashi Ishii clinic120
Active, not recruiting
Phase 1
Clinical study to investigate the efficacy, the safety and immunogenicity of Wilate in children <6 years of age with inherited von Willebrand disease (VWD) - WIL-14Wllebrand diseaseMedDRA version: 8.1Level: PTClassification code 10047715Term: Von Willebrand's disease
EUCTR2005-001426-84-FROCTAPHARMA AG17
Active, not recruiting
Phase 1
Clinical Trial to investigate the efficacy and safety of ANGOCIN® Anti-Infekt N against placebo preventing urinary tract infections in catheterized patientsProphylaxis of catheter-associated chronically inflammatory recurring urinary tract infections in adult patientsMedDRA version: 20.0Level: LLTClassification code 10046544Term: Urinary infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.0Level: LLTClassification code 10007810Term: Catheter related infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2016-004842-27-DERepha GmbH100